Acelrx pharmaceuticals announces publication of clinical data finding potential benefits of nafamostat compared to regional citrate for anticoagulation of the dialysis circuit

Study results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation. hayward, calif.

ACRX Ratings Summary

ACRX Quant Ranking